Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results

Authors :: David Van Brummelen
Marius Giurescu
Wolff Schmiegel
Marc Peeters
Uwe M. Martens
Volker Heinemann
Svein Dueland
Colin D. Weekes
Michael Teufel
Vittorio Luigi Garosi
Jean-Luc Van Laethem
Anke Schulz
Patrick Michl
Henrik Seidel
Hanno Riess
Barrett H. Childs
Source :: ResearcherID
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 4129 Background: Refametinib is a potent oral allosteric MEK 1/2 inhibitor with both single-agent and synergistic activity in combination with gemcitabine in preclinical models of pancreas cancer (...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
MEK inhibitor
Cancer
Phases of clinical research
medicine.disease
Gemcitabine
medicine.anatomical_structure
Internal medicine
Metastatic pancreatic cancer
Medicine
Biomarker (medicine)
business
Refametinib
Pancreas
medicine.drug

Tools